Why Cassava Sciences Stock Crushed It in September
Cassava Sciences (NASDAQ: SAVA), a clinical-stage biotech, certainly had a month to remember in September. Specifically, the biotech's stock gained an eye-popping 273.7% last month, according to data provided by S&P Global Market Intelligence.
Cassava's shares exploded higher in September for two interrelated reasons:
Image source: Getty Images.
Source Fool.com
